Stem Cell Exosomes Loaded with miR-214 Show Promise for Repairing Crushed Sciatic Nerves in Rats

A damaged peripheral nerve can regenerate, but slowly and often incompletely, leaving patients with lasting weakness, numbness, or chronic pain. Researchers have now reported a potential way to accelerate that recovery using tiny membrane-bound vesicles secreted by stem cells, engineered to carry an extra payload of a specific regulatory RNA molecule. In a study conducted on rats, exosomes derived from muscle-resident stem cells and enriched with microRNA-214 appeared to promote regeneration of the crushed sciatic nerve by activating a well-known intracellular signaling pathway while simultaneously suppressing a molecular brake on repair.

…

The retraction notice itself contains an unusual element worth pausing over: the journal states that the manuscript “requires substantial revisions that go beyond the scope of a standard correction” and that retraction was chosen “to allow for a comprehensive revision and resubmission.” This framing sits somewhat awkwardly with standard publishing norms, in which retraction is generally understood as a permanent withdrawal of a paper from the scientific record, not a temporary holding state. In conventional practice, a paper that needs revision before its claims can be trusted would typically receive an editorial expression of concern, a correction, or, in the most serious cases, retraction without the expectation of resubmission. The suggestion that a retracted paper might return in revised form is rare, and readers who encounter the original 2023 article in databases or citation lists should understand that, as of the retraction notice, the paper’s findings cannot be relied upon regardless of whether a revised version ever appears.

The technical concerns that triggered the retraction centered on image integrity, specifically duplications identified in Figures 3B and 4D of the original paper. Image duplication is one of the most commonly cited categories in post-publication scrutiny of the life sciences, and it can arise in several distinct ways. Sometimes the same microscopy field or blot image is inadvertently presented twice, for example when a control panel is mistakenly reused in an experimental condition panel. In other cases, duplication reflects systematic problems with how data were generated, selected, or assembled, which raises deeper questions about the reliability of the entire dataset. The retraction notice does not specify which scenario applies here, and the fact that the journal concluded the problems required “substantial revisions” rather than a simple correction suggests the issues were not trivially confined to a mislabeled panel. Without access to the underlying raw data, readers cannot determine how far the duplications extend or whether the central conclusions about miR-214, PTEN, and the JAK2/STAT3 pathway would survive a careful reanalysis.

The authors’ silence adds another layer of concern. The notice states plainly that the authors “have not responded to correspondence regarding this retraction.” In the standard workflows recommended by the Committee on Publication Ethics, editors are expected to seek the authors’ response to integrity concerns before acting, and a cooperative process often produces a correction or clarification that preserves most of a paper’s value. When authors fail to engage, editors must proceed on the available evidence, and the resulting notices tend to be more categorical. Non-response also deprives the scientific community of context that only the authors could provide, such as whether original image files exist, whether the duplications stem from assembly errors, and whether the key experiments can be repeated from archived samples. For a paper whose central claim rests on a chain of molecular interactions in a living tissue model, that lost context is not easily reconstructed by outsiders.

It is worth considering what the original paper claimed, because the scientific premise remains interesting even as the published evidence is now withdrawn. Peripheral nerve injuries are common, ranging from traumatic lacerations and crush injuries to compression neuropathies, and while the peripheral nervous system retains a genuine capacity for regeneration unlike the central nervous system, that capacity is slow and often functionally incomplete. Axons regrow at roughly a millimeter per day under favorable conditions, and the quality of recovery depends on factors including the distance the regenerating axon must travel, the degree of scarring at the injury site, the survival and activation of Schwann cells that guide and support regrowth, and the timely reinnervation of target muscle, which deteriorates the longer the muscle remains denervated. Any intervention that reliably accelerates or improves the completeness of regeneration would address a substantial unmet clinical need, which is why the field has explored approaches ranging from surgical grafting techniques and nerve guides to electrical stimulation, pharmacological agents, and cell-based therapies.

Exosomes sit within a broader family of extracellular vesicles that cells release naturally, and they have attracted intense interest as mediators of intercellular communication and as candidate therapeutics. Unlike whole-cell transplantation, exosome-based approaches avoid some of the practical obstacles that complicate cell therapy, including immune rejection of transplanted cells, risks of uncontrolled proliferation or inappropriate differentiation, and the logistical challenges of manufacturing, storing, and delivering living cells to the site of injury. Exosomes carry proteins, lipids, and nucleic acids, including microRNAs, from their cell of origin, and accumulating evidence suggests that a meaningful fraction of the regenerative effects attributed to transplanted stem cells may actually be mediated by the vesicles those cells secrete rather than by the cells themselves engrafting and integrating into tissue. This has motivated efforts to isolate exosomes from various stem cell sources, characterize their cargo, and in some cases engineer them to carry elevated levels of specific therapeutic molecules.

MicroRNA-214, the cargo highlighted in the retracted study, is a small regulatory RNA with documented roles in multiple biological processes, including muscle biology, where it was originally characterized as a myogenic regulator, as well as in fibrosis, inflammation, and cell survival. Its proposed relevance to nerve repair in the retracted paper rested on the idea that delivering extra copies of this microRNA to injured nerve tissue would suppress PTEN, a gene encoding a well-known phosphatase that acts as a brake on the PI3K/AKT growth-signaling pathway. PTEN is famous in regeneration biology because its suppression in neurons can enhance axonal growth, an effect demonstrated in central nervous system neurons where intrinsic regenerative capacity is otherwise very limited. The retracted paper extended this logic to the peripheral nerve setting and added a second layer, claiming that the resulting signaling cascade activated the JAK2/STAT3 pathway, a signaling axis involved in cytokine responses, cell survival, and proliferation that has been implicated in Schwann cell activation and repair-associated glial phenotypes. The appeal of the design was that a single engineered vesicle payload could, in principle, coordinate multiple pro-regenerative programs at once.

That mechanistic elegance is precisely why the retraction matters beyond the fate of one paper. If the image-level concerns undermine the experimental evidence for the miR-214–PTEN–JAK2/STAT3 axis in this context, other groups considering follow-up work lose the foundation they would have built on. Conversely, if the underlying biology is sound and only the presentation of data was flawed, the field loses a potentially useful therapeutic concept to a preventable failure of research practice. Either way, the episode illustrates how dependent the microRNA and extracellular vesicle literature is on the integrity of relatively small, hard-to-verify datasets. MicroRNA functional studies typically rely on gain- and loss-of-function experiments, reporter assays, and downstream pathway readouts, and image-based figures such as immunoblots, histological sections, and fluorescence micrographs carry much of the evidentiary weight. When panels within such figures are duplicated, the reader cannot tell whether independent biological replicates actually support the claimed effects.

The timeline of the case is also instructive. The original article was published on 26 May 2023, and the retraction notice was received on 8 October 2026, accepted the same day, and published on 16 October 2026. More than three years therefore elapsed between publication and retraction. Such intervals are not unusual in research integrity cases, which often require extensive correspondence, image forensics, consultation with institutional officials, and internal editorial review, but they highlight a structural challenge for the scientific literature: during the intervening years, the paper remained indexed, citable, and potentially influential. Readers who cited or built on the work during that period had no signal that concerns existed. The rapid acceptance of the retraction once it entered the editorial pipeline, received and accepted on the same day, suggests the deliberation had largely concluded before the formal notice was processed, with the approval of the journal’s Chief Editors and the Chief Executive Editor providing the final authorization.

For readers assessing the broader literature on stem cell exosomes and nerve repair, several practical lessons follow. First, retracted papers should be treated as withdrawn from the evidentiary base, and citation databases increasingly flag them, but manual literature reviews can still surface retracted work without warning, so checking retraction status remains essential when drawing on older studies. Second, the specific combination of claims in this paper, involving engineered exosome cargo, a targeted tumor suppressor, and a canonical signaling pathway, represents a pattern common in the regenerative medicine literature, where mechanistic narratives are assembled from multiple molecular links. Each link depends on its own experiments, and integrity problems in any part of the chain can compromise the whole. Third, the fact that the journal framed retraction as a prelude to possible resubmission means that any future revised version of this work would need to be evaluated on its own merits, with fresh scrutiny of the data, rather than being accepted as a continuation of the original paper’s findings. Until and unless such a revised study appears and passes independent review, the claim that miR-214-enriched muscle-derived stem cell exosomes promote sciatic nerve regeneration through PTEN targeting and JAK2/STAT3 activation should be regarded as unsupported by peer-reviewed evidence.

Finally, the case underscores the role of post-publication vigilance in modern science. The concerns here were raised after publication, presumably by readers or reviewers who noticed the duplicated images, and the journal’s response, culminating in a formal retraction approved at the highest editorial level, reflects the increasing willingness of publishers to act on integrity issues even years after the fact. For a field as clinically motivated as peripheral nerve regeneration, where patients and clinicians await genuinely effective therapies, maintaining a trustworthy record of what has and has not been demonstrated is not an administrative formality but a prerequisite for progress.

Subject of Research: Neuroscience

Article Title: Retraction: Muscle-derived stem cell exosomes with overexpressed miR-214 promote the regeneration and repair of rat sciatic nerve after crush injury to activate the JAK2/STAT3 pathway by targeting PTEN

Article References: Frontiers Editorial Office (2026). Retraction: Muscle-derived stem cell exosomes with overexpressed miR-214 promote the regeneration and repair of rat sciatic nerve after crush injury to activate the JAK2/STAT3 pathway by targeting PTEN. Frontiers in Molecular Neuroscience, 19, Article 2021959. https://doi.org/10.3389/fnmol.2026.2021959

Image Credits: AI Generated

DOI: 10.3389/fnmol.2026.2021959

Keywords: exosomes, miR-214, sciatic nerve, peripheral nerve injury, JAK2/STAT3, PTEN, muscle-derived stem cells, nerve regeneration, microRNA, rat model, regenerative medicine, cell-free therapy